Team:Evry

From 2013.igem.org

(Difference between revisions)
 
(225 intermediate revisions not shown)
Line 1: Line 1:
-
{{:Team:Evry/template_vo}}
+
{{:Team:Evry/template_home}}
 +
 
<html>
<html>
-
<a href='https://2013.igem.org/Team:Evry/Home' title='Vers la page française'> <img src='https://static.igem.org/mediawiki/2013/b/b9/Francais.jpg'/></a>
+
<div id="mainTextcontainer">
-
<h1 align='center'>Welcome to the Iron coli Project</h1>
+
<h1>Welcome to the <b><span style="color:#bb8900">Iron Coli Project</span></b> Home Page</h1>
 +
 
 +
<br />
 +
 
 +
<p align="center"><b>The aim of our team this year is to design and realize a <em>treatment for hemochromatosis and thalassemia</em> using synthetic biology with an <em>integrated human practice</em> and <em>modeling approach</em>. </b></p>
 +
 
 +
<br /><br />
 +
 
 +
<div>
 +
<div style="float:right;width:49%;margin-left:1%;">
 +
<h3 align="center">The Team</h3>
 +
<img src="https://static.igem.org/mediawiki/2013/8/89/IronColiTeamatthejamboree.jpg" alt="team photo" width="100%"/>
 +
</div>
 +
</div>
 +
 
 +
<h3 align="center">Abstract</h3>
-
<h2 align='center'>Abstract</h2>
 
<p>
<p>
-
This year we choose to develop a project which deals with hematologic diseases. We focused specifically on diseases with an iron overload disorder. Among those type of diseases, we were interested in the hereditary hemochromatosis and hemosiderosis. In the case of hereditary hemochromatosis, the iron overload disorder is a direct consequence of this disease. While in the hemosiderosis the iron overload is due to a metabolic perturbation.
+
Our project focuses on developing a novel treatment for <a href="https://2013.igem.org/Team:Evry/Project_diseases"><em>hematological disorders</em></a>  caused by an <a href="https://2013.igem.org/Team:Evry/Project_metabolism"><em>iron overload</em></a>, such as hemochromatosis and thalassemia. These autosomal recessive disorders have symptoms including cirrhosis, arthritis, and heart failure, which result from overabsorption of iron from the duodenum. Although these are among the most common heritable diseases, treatment options are limited. Even today patients are mostly treated by frequent bloodletting, which <a href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions"><em>many people cannot support</em></a>. The aim of our project is to combat these diseases at the source by developing a therapy that prevents the intestinal absorption of iron.
</p>
</p>
 +
<p>
<p>
-
Today the iron overload can be treated by bloodletting in the case of the hemochromatosis but it cannot be used as a treatment of hemosiderosis because patients suffer of anaemia. In our project we want to solve this problem acting directly at the iron absorption source, in the intestines.
+
We engineer the <i>Escherichia coli</i> <a href="https://2013.igem.org/Team:Evry/Project_FUR"><em>Ferric Uptake Regulation</em></a> (FUR) system using a <a href="https://2013.igem.org/Team:Evry/Inverter"><em>genetic inverter</em></a> so that they produce siderophores (<a href="https://2013.igem.org/Team:Evry/Chelator"><em>iron chelators</em></a>) in response of high concentrations of iron. These engineered bacteria are delivered to the patient's intestine by encapsulating them in an ingestible polymer (<a href="https://2013.igem.org/Team:Evry/Pill_design"><em>capsule</em></a>)  that specifically degrades in the duodenum. Once released into the intestine, the bacteria respond to ambient iron by secreting elevated levels of siderophores, thereby chelating the iron to prevent its absorption by the patient.
-
</p>
+
-
<p>
+
-
Using the Ferric Uptake Regulation (FUR) system to control siderophore (iron chelator) biosynthesis, we engineered a bacterium giving it the ability to produce these siderophores in response of iron. In order to limit the iron overload in the patient, this bacterium would be placed in the intestines.
+
</p>
</p>
-
<h2>Baptiste</h2>
 
-
<p>This year we choose to develop a project about hematologic diseases which implie iron overload disorder. We focus on hemosiderosis, heriditary or secondary (due to a metabolic perturbation). Nowadays, the iron overload can be treated by invasive method as blodletting, which cannot be used for anemic patient, or by transfusion of iron chelator which have lot of sides effect.</p>
+
<script type="text/javascript" src="https://2012.igem.org/Team:Evry/wz_jsgraphics.js?action=raw"></script>
-
<p>
+
<script type="text/javascript" src="https://2012.igem.org/Team:Evry/mapper.js?action=raw"></script>  
-
Our project is to design a new treatment of hemosiderosis using engineered bacteria, to solve the overabsorption directly at the iron absorption source, in the intestines.</p>
+
-
<p>
+
-
Using the Ferric Uptake Regulation (FUR) system, naturally active in E.coli during iron starvation period, to control siderophore (iron chelator) byosynthesis, we design a bacterium able to produce these siderophores in response of hight iron concentration. Bacteria would be placed in capsule and ingest during a meal, and then could limit iron absorption by chelating iron on the duodenum.
+
-
</p>
+
-
<p>
+
-
As this treatment could have impact, positive or negative, on patient life, we model the possible effects of such a treatment on organism (and other truc de modelleux.) We also note down expert opinion to improve the safety and our treatment.
+
 +
<div style="clear:both;"></div>
 +
<h3 align="center">Overview of the project and the achievements</h3>
 +
 +
<center>
 +
<div align="center">
 +
<img align="center" id="ModMap" src="https://static.igem.org/mediawiki/2013/4/4d/IGEM_Timeline.png" width="850" class="mapper" usemap="#overview_link" style="z-index:500;"/>
 +
 +
<map name="overview_link">
 +
<area shape="rect" coords="60,61,210,82" target="Project FUR" href="https://2013.igem.org/Team:Evry/Project_FUR" />
 +
<area shape="rect" coords="60,82,210,103" target="Results" href="https://2013.igem.org/Team:Evry/Results" />
 +
<area shape="rect" coords="60,103,210,124" target="Results" href="https://2013.igem.org/Team:Evry/Results#AceB_GFP" />
 +
<area shape="rect" coords="228,63,378,82" target="Inverter" href="https://2013.igem.org/Team:Evry/Inverter" />
 +
<area shape="rect" coords="228,101,378,120" target="Model"  nohref="nohref" />
 +
<area shape="rect" coords="228,82,378,101" target="Results" href="https://2013.igem.org/Team:Evry/Results#Inverter" />
 +
<area shape="rect" coords="399,63,556,80" target="Chelator" href="https://2013.igem.org/Team:Evry/Chelator" />
 +
<area shape="rect" coords="399,103,556,120" target="Results" href="https://2013.igem.org/Team:Evry/Chelator#caracterization_siderophore" />
 +
<area shape="rect" coords="399,83,556,100" target="Chelator" href="https://2013.igem.org/Team:Evry/Chelator#Second_design" />
 +
<area shape="rect" coords="633,76,841,94" target="Expert consultation" href="https://2013.igem.org/Team:Evry/HumanPractice/Expert_consultation" />
 +
<area shape="rect" coords="633,156,841,174" target="Philosophy" href="https://2013.igem.org/Team:Evry/Philosophy" />
 +
<area shape="rect" coords="633,136,841,154" target="Safety" href="https://2013.igem.org/Team:Evry/Safety" />
 +
<area shape="rect" coords="633,116,841,134" target="Seminar" href="https://2013.igem.org/Team:Evry/Seminar" />
 +
<area shape="rect" coords="633,96,841,114" target="Patients perceptions" href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions" />
 +
 +
<!--
 +
<area shape="rect" coords="443,457,659,474"  href="https://2013.igem.org/Team:Evry/Model1#Results" />
 +
<area shape="rect" coords="443,517,659,547"  href="https://2013.igem.org/Team:Evry/Model1#Conclusion" />
 +
<area shape="rect" coords="443,497,659,514"  href="https://2013.igem.org/Team:Evry/Model1#Results" />
 +
<area shape="rect" coords="443,477,659,494"  href="https://2013.igem.org/Team:Evry/Model1#Results" />
 +
<area shape="rect" coords="164,398,419,414"  href="https://2013.igem.org/Team:Evry/Model3#Description" />
 +
<area shape="rect" coords="164,458,419,474"  href="https://2013.igem.org/Team:Evry/Model3#Conclusion" />
 +
<area shape="rect" coords="164,438,419,454"  href="https://2013.igem.org/Team:Evry/Metabolism_model" />
 +
<area shape="rect" coords="164,418,419,434"  href="https://2013.igem.org/Team:Evry/Model3#Results" />
 +
-->
 +
 +
<area shape="rect" coords="118,276,283,294"  target="Norms from the European Pharmacopeoa" href="https://2013.igem.org/Team:Evry/Pill_design#norm" />
 +
<area shape="rect" coords="118,296,283,314"  target="Overcoming the acidity" href="https://2013.igem.org/Team:Evry/Pill_design#acidity" />
 +
<area shape="rect" coords="303,276,497,294"  target="Dissolution in the jejunum" href="https://2013.igem.org/Team:Evry/Pill_design#jejunum"/>
 +
<area shape="rect" coords="303,294,497,312"  target="Survival after the process" href="https://2013.igem.org/Team:Evry/Pill_design#conclusion" />
 +
 +
<area shape="rect" coords="631,175,794,195" href="https://2013.igem.org/Team:Evry/Economy" />
 +
<area shape="rect" coords="159,402,448,423" href="https://2013.igem.org/Team:Evry/Modelmeta1" />
 +
<area shape="rect" coords="159,443,448,464" href="https://2013.igem.org/Team:Evry/Metabolism_model" />
 +
<area shape="rect" coords="159,381,448,402" href="https://2013.igem.org/Team:Evry/Modelmeta2" />
 +
<area shape="rect" coords="159,422,448,443" href="https://2013.igem.org/Team:Evry/Modelmeta3" />
 +
<area shape="rect" coords="159,463,448,484" href="https://2013.igem.org/Team:Evry/pop_scale" />
 +
<area shape="rect" coords="159,483,448,504" href="https://2013.igem.org/Team:Evry/Modelmeta3" />
 +
 +
<area shape="rect" coords="462,464,595,484" href="https://2013.igem.org/Team:Evry/Modeltr1" />
 +
<area shape="rect" coords="462,484,595,504" href="https://2013.igem.org/Team:Evry/Modeltr1" />
 +
<area shape="rect" coords="462,504,595,524" href="https://2013.igem.org/Team:Evry/Modeltr2" />
 +
<area shape="rect" coords="464,524,673,558" href="https://2013.igem.org/Team:Evry/Modeltr2" />
 +
 +
</map>
 +
</div>
 +
</center>
 +
 +
 +
<div style="clear:both;">
 +
 +
</div>
 +
 +
</div>
 +
</div>
 +
 +
<!--
 +
<script type="text/javascript">
 +
alert("Our team is proud to announce that we were awarded a gold medal and the Best Human Practice price at the european jamboree! We are going to Boston.\n\nUnfortunately, we are missing a few thousands of euros to be capable of finishing the competition. If you are a company and would like to sponsor our team, please contact us at igemevry@gmail.com.")
 +
</script>
 +
-->
-
<script type='text/javascript'>writeFooter()</script>
 
</html>
</html>
 +
 +
{{:Team:Evry/foot}}

Latest revision as of 18:38, 28 October 2013

Iron coli project

Welcome to the Iron Coli Project Home Page


The aim of our team this year is to design and realize a treatment for hemochromatosis and thalassemia using synthetic biology with an integrated human practice and modeling approach.



The Team

team photo

Abstract

Our project focuses on developing a novel treatment for hematological disorders caused by an iron overload, such as hemochromatosis and thalassemia. These autosomal recessive disorders have symptoms including cirrhosis, arthritis, and heart failure, which result from overabsorption of iron from the duodenum. Although these are among the most common heritable diseases, treatment options are limited. Even today patients are mostly treated by frequent bloodletting, which many people cannot support. The aim of our project is to combat these diseases at the source by developing a therapy that prevents the intestinal absorption of iron.

We engineer the Escherichia coli Ferric Uptake Regulation (FUR) system using a genetic inverter so that they produce siderophores (iron chelators) in response of high concentrations of iron. These engineered bacteria are delivered to the patient's intestine by encapsulating them in an ingestible polymer (capsule) that specifically degrades in the duodenum. Once released into the intestine, the bacteria respond to ambient iron by secreting elevated levels of siderophores, thereby chelating the iron to prevent its absorption by the patient.

Overview of the project and the achievements

Retrieved from "http://2013.igem.org/Team:Evry"